AG
TVRD

Aperio Group’s Tvardi Therapeutics TVRD Stock Holding History

Aperio Group’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$151K Buy
+278
New +$146K ﹤0.01% 2349
2019
Q3 		– Sell
-114
Closed -$88K – 2792
2019
Q2 		$88K Buy
+114
New +$80.1K ﹤0.01% 2421

Other funds holding TVRD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Aperio Group's TVRD Position: Q4 2020 in Review

Aperio Group opened a new position in Tvardi Therapeutics (TVRD) in Q4 2020: 278 shares worth $151K. The stake represents ﹤0.01% of the portfolio and ranks #2349 among its holdings. This is a return to the name: Aperio Group previously reported a position in TVRD as recently as Q2 2019.

Aperio Group first reported a position in TVRD in Q2 2019 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold TVRD as of Q4 2020.

  • Aperio Group held 278 shares of Tvardi Therapeutics worth $151K as of Q4 2020.
  • Tvardi Therapeutics was a new Aperio Group position in Q4 2020.
  • Tvardi Therapeutics made up ﹤0.01% of Aperio Group's portfolio in Q4 2020, its #2349 holding.
  • Aperio Group first reported a position in Tvardi Therapeutics in Q2 2019 and has held it in 2 quarters since.
  • 155 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.